<DOC>
	<DOCNO>NCT00277394</DOCNO>
	<brief_summary>The objective study compare safety innohep® Unfractionated Heparin ( UFH ) term clinically relevant bleeding elderly patient impair renal function initial treatment acute Deep Venous Thrombosis ( DVT ) . The primary response criterion percentage patient clinically relevant bleeding event prior day 90 +/- 5 .</brief_summary>
	<brief_title>Innohep® Elderly Patients With Impaired Renal Function Treated Acute Deep Vein Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<criteria>Patients symptomatic objectively confirm Venous Thromboembolism ( VTE ) ( low limb deep venous thrombosis ( DVT ) pulmonary embolus ( PE ) ) mandatory presence objectively confirm treatment require DVT , i.e . symptomatic objectively confirm distal DVT objectively confirm , symptomatic asymptomatic proximal DVT ( confirmation DVT perform ultrasonography venography within 48 hous prior randomisation ) Patients indication DVT treatment SC Low Molecular Weight Heparin ( LMWH ) Unfractionated Heparin ( UFH ) follow Oral Anticoagulant ( OAC ) least 90 day Hospitalized patient , SC anticoagulant treatment , follow , specify protocol , daily basis either hospital outpatient set Patients 75 year creatinine clearance less equal 60 mL/min calculate accord CockcroftGault formula Patients 70 year creatinine clearance less equal 30 mL/min calculate accord CockcroftGault formula Patients receive high dose ( i.e . equivalent dose recommend treatment DVT ) UFH LMWH thrombolytic agent within last 4 week except UFH/LMWH last 36 hour prior randomisation Patients oral anticoagulant treatment ( vitamin Kantagonists ) within last 1 week prior randomisation Patients symptomatic venous thromboembolism ( VTE ) require thrombolytic therapy invasive intervention End stage renal disease patient require dialysis Surgery within 2 week prior randomisation plan surgery , epidural anaesthesia and/or spinal anaesthesia SC anticoagulant treatment period Planned use acetylsalicylic acid dose 300 mg/day , NSAID Dextran 40 randomisation SC anticoagulant treatment period Patients current overt bleeding know haemorrhage condition ( e.g . active G.I . ulcer ) Patients platelet count &lt; 100 x 10 9/L Patients know history heparininduced thrombocytopenia Patients know severe hepatic insufficiency manifest international normalized ratio ( INR ) great equal 1.5 Patients uncontrolled severe hypertension i.e . systolic blood pressure &gt; 220 mm Hg diastolic blood pressure &gt; 120 mm Hg least 2 measurement within 24 hour prior randomisation Patients ischaemic stroke within last 1 week prior randomisation Patients know haemorrhagic stroke within 3 month prior randomisation Patients know bacterial endocarditis within 3 month prior randomisation</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Acute , symptomatic objectively confirm DVT</keyword>
</DOC>